February 26, 2024 7:32am

A lot more LPS (loss-per-share) earnings to be reported

Earnings: Tuesday - RGNX, Wednesday - MDXG, EDIT, VYGR and Thursday - BLFS

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi provides the extenuating factors of share pricing.

 

Monday: The pre-open Dow futures are DOWN -0.09% or (-36 points), the S&P futures are DOWN -0.07 % or (-3 points) as the Nasdaq futures are DOWN -0.08% or (-14-points)

Futures are whimping to the down side on Monday,

European markets lower,

Asia Pacific markets were mixed as Japan bounded and China fell.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Friday indexes closed mixed as the Dow closed UP +62.42 points or +0.16%, the S&P closed UP +1.77 points +0.03% while the Nasdaq closed DOWN -44.80 points or -0.28%

And my Friday covered universe was negative with 10 incliner, 23 decliners and 2 flats; ending with a positive close of 22 incliners, 13 decliners and 0 flats

 

Friday’s night RegMed Investors (RMi) Closing Bell: “yesterday’s ups and downs were switching positions. Trading is re-calibrating expectation as upside profit taking surges even as my sector group closes positive.” …  https://www.regmedinvestors.com/articles/13343

Q1/24: February – 1 market holiday, 9 positive and 7 negative closes

  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

I am passing on forecasting the daily indications – the aftermarket seems sloping …  the pre-open market is waiting for an all-clear alarm, based on inflation-oriented January durable orders data on Tuesday and January wholesale inventories on Wednesday.

  • Still a mix of ups, downs and just unknowns …mixed of some ups, fewer downs and a flat

 

The BOTTOM LINE: The cell and gene therapy sector equities had a strong session on Friday after Thursday after Wednesday’s weak yet, positive session after Tuesday’s negative session, and last Monday’s holiday.

  • The remainder of the month’s trading sessions will be critical as the RegMed sector continues earnings’ in LPS (loss-per-share) season, estimates and consensus which set market reaction and will report “runways” and those whose cash positions render their future questionable.

 

I have seen 1 net income for the Q4 (but a FY23 loss) – CRISPR Therapeutics (CRSP).

7 have reported … NTLA, CRSP, IONS, SAGE, RARE, BPMC and ALNY.

Next week: Tuesday -RGNX, Wednesday – MDXG, EDIT, VYGR and Thursday - BLFS

 

I reiterate, “Don't chase the cell and gene therapy sector, especially with the Nasdaq extended.”

Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

 

All of these indexes rebounded from around their 21-day exponential moving averages.

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.